Abstract:

Objective To evaluate the efficacy and side effects of pemetrexed combined with carboplatin regimen in the treatment for patients with advanced nonsquamous nonsmall cell lung cancer（NSCLC）. Methods Fifty-five advanced nonsquamous NSCLC patients confirmed with pathology or cytology were enrolled in this study. All the patients received pemetrexed（500mg／m² iv d₁） and carboplatin（AUC=5 iv d₁or d₂） with 21 days as a cycle. Each patient received at least 2 cycles. The efficacy and side effects were observed. Results The efficacy of the 55 patients could be evaluated. Four cases got CR， 14 achieved PR， 20 reached SD and 17 were PD. The effective rate was 32.7％ and the disease control rate was 69.1％.The median progression free survival was 5.5 months（95％CI：4.4-6.6 months）. The patients of ECOG score 0-1 compared with ECOG score 2， and first-line treatment compared with secondline treatment had better efficacy（P＜0.05）. The main side effects were myelosuppression， gastrointestinal response， fatigue and peripheral neurotoxicity， and mainly in grade 1-2. Conclusion Administration of pemetrexed combined with carboplatin regimen is beneficial to patients with advanced nonsquamous NSCLC， and the toxic effects are tolerable.